UPPSALA, Sweden, Dec. 20 /CNW/ - Import, sales and distribution of
Phadia's allergy, asthma and autoimmunity diagnostics products,
including ImmunoCAP and EliA, have been commercially approved by the
Following official approval, Phadia will begin marketing a broad
portfolio of diagnostic products to major commercial laboratories,
hospitals and research institutes as well as to individual physicians.
"The Indian market is strategically important to Phadia with high
economic growth and an expanding middle class demanding new and better
healthcare solutions," says Jean Forcione, Chief Operating Officer,
With allergy prevalence estimated at over 30 per cent of the Indian
population of 1.2bn people and the laboratory market expected to grow
close to 20 per cent, Phadia sees substantial growth potential.
Phadia opened its own subsidiary in India in April 2010 and already
works closely with several of the major commercial laboratories and
major private hospital chains.
PhadiaAB is a global leader in allergy, asthma and autoimmunity
diagnostics. Phadia develops, manufactures and markets complete blood
test systems to manage and support clinical diagnosis. Phadia has
marketing companies in more than 20 countries and distributors in more
than 60 countries. Phadia is owned by the leading European buyout firm
Cinven. For more information please visit http://www.phadia.com
For further information: For further information:
VP Marketing, Corporate Communication, Scientific Affairs